Patent intelligence · US
US 10350239
Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium c…
Patent details — US 10350239
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 16, 2019
- Expiration
- Jul 11, 2039
- Applicant
- Propanc Pty Ltd
- Claims
- 15
- CPC classes
- A61K, A61K2300/00, A61K31/095, A61K31/21
Quick answer
US 10350239 (Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent) is held by Propanc Pty Ltd. Status: granted. Granted Jul 16, 2019. Expires Jul 11, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Propanc Pty Ltd
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K2300/00, A61K31/095, A61K31/21, A61K33/04, A61K38/47
More from Propanc Pty Ltd
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 10350239?
US 10350239 (Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent) is held by Propanc Pty Ltd. Status: granted. Granted Jul 16, 2019. Expires Jul 11, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10350239?
Propanc Pty Ltd is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 10350239 expire?
Our index shows an expiration date of Jul 11, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.